Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Krystal BiotechFRA:4KB -1.84%59 Days Sales Outstanding is 103.02 as of Jun. 2026, which is 5% below its 10-year median of 108.89. GuruFocus rates FRA:4KB with a GF Score™ of 59/100 and a GF Value™ of €302.02 (Fairly Valued). The stock has 3 warning signs investors should review. Among 841 Biotechnology companies, Krystal Biotech ranks worse than 73.13% on this metric.
Krystal Biotech (FRA:4KB) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
Krystal Biotech Days Sales Outstanding Related Terms
Krystal Biotech Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:4KB vs AXSM, APGE, IONS: Days Sales Outstanding Comparison
For the Biotechnology subindustry, Krystal Biotech's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's Days Sales Outstanding falls into.
Krystal Biotech Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 103.02 mean?
Krystal Biotech (FRA:4KB) has a Days Sales Outstanding of 103.02 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Krystal Biotech and its competitors. This is near median its historical median of 108.89. Over the past decade, Krystal Biotech's Days Sales Outstanding has ranged from 92.21 to 302.66. According to the industry distribution chart, Krystal Biotech ranks #615 out of 841 companies in the Biotechnology industry, placing it in the top 73.1%.
Is Krystal Biotech's Days Sales Outstanding too high?
Krystal Biotech's current Days Sales Outstanding of 103.02 is near median its 10-year median of 108.89. Over the past 10 years, this metric has ranged from a low of 92.21 to a high of 302.66. The Biotechnology industry median Days Sales Outstanding is 68.98. Krystal Biotech's value of 103.02 is 49.3% above this industry median. Based on the distribution chart, Krystal Biotech ranks #615 out of 841 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Krystal Biotech has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's Days Sales Outstanding compare to AXSM and APGE?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #615 out of 841 companies for Days Sales Outstanding. This places Krystal Biotech in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. Krystal Biotech's value of 103.02 is 49.3% above this benchmark. Historically, Krystal Biotech's own Days Sales Outstanding has ranged from 92.21 to 302.66 over the past decade. While the company's 10-year median is 108.89 vs. the industry median of 68.98, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current Days Sales Outstanding of 103.02 is 49.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current Days Sales Outstanding is 103.02, which is near median its own 10-year median of 108.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Fairly Valued. The stock's GF Value™ is €302.02, compared to a current price of €288.00 — trading 4.6% below its estimated fair value. The current Days Sales Outstanding is 103.02, which is near median its 10-year median of 108.89 and 49.3% above the Biotechnology industry median of 68.98. Krystal Biotech's overall GF Score™ is 59/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current Days Sales Outstanding is 103.02 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be undervalued.
The current stock price of €288.00 is trading 4.6% below its estimated GF Value™ of €302.02.
GuruFocus considers Krystal Biotech to be Fairly Valued.
Key valuation signals for FRA:4KB:
Days Sales Outstanding: 103.02 (near median its 10-year median of 108.89)
GF Value™: €302.02 vs. price of €288.00 (4.6% below fair value)
Industry Position: 49.3% above the Biotechnology median (#615 of 841)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
59GF Score
Get the complete analysis for FRA:4KB
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
